Ketamine in Bariatric Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by University of Padova.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
University of Padova Identifier:
First received: September 14, 2012
Last updated: November 7, 2012
Last verified: November 2012

Ketamine may improve recovery from bariatric surgery.

Condition Intervention Phase
Morbid Obesity
Drug: ketamine
Drug: fentanyl
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Ketamine on Recovery From Bariatric Surgery

Resource links provided by NLM:

Further study details as provided by University of Padova:

Primary Outcome Measures:
  • pain level [ Time Frame: postoperatively, up to 3 months ] [ Designated as safety issue: Yes ]
  • mood level [ Time Frame: postoperatively, up to 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • total dosages of analgesic and muscle relaxant drugs [ Time Frame: postoperatively, up to 3 months ] [ Designated as safety issue: Yes ]
  • postanesthetic recovery [ Time Frame: postoperatively, up to 24 hours ] [ Designated as safety issue: Yes ]
  • satisfaction of the patient and of the surgeon [ Time Frame: day 1 ] [ Designated as safety issue: No ]
  • pulse oximetry saturation [ Time Frame: postoperatively, up to 24 hours ] [ Designated as safety issue: Yes ]
  • lung volumes [ Time Frame: postoperatively, up to 48 hours from end of surgery ] [ Designated as safety issue: Yes ]
  • antihemetic drug dosage [ Time Frame: postoperatively, up to 24 hours ] [ Designated as safety issue: Yes ]
  • vasoactive drugs [ Time Frame: intraoperatively and up to 24 hours from surgery end ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 90
Study Start Date: June 2012
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ketamine
patients will receive ketamine at induction
Drug: ketamine
Active Comparator: fentanyl
patients will receive fentanyl at induction
Drug: fentanyl


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > 18
  • obesity (Body Mass Index > 30)
  • ASA classificazion < 4
  • candidate to bariatric surgery

Exclusion Criteria:

  • known or presumed pregnancy
  • previous surgery on the airway, esophagus or stomach
  • uncontrolled psychiatric symptomatology
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01724983

Azienda Ospedaliera
Padova, PD, Italy, 35121
Sponsors and Collaborators
University of Padova
Principal Investigator: Ulderico Freo, MD Università di Padova
  More Information

No publications provided

Responsible Party: University of Padova Identifier: NCT01724983     History of Changes
Other Study ID Numbers: KET2271
Study First Received: September 14, 2012
Last Updated: November 7, 2012
Health Authority: Italy: Ministry of Health

Keywords provided by University of Padova:

Additional relevant MeSH terms:
Obesity, Morbid
Body Weight
Nutrition Disorders
Signs and Symptoms
Adjuvants, Anesthesia
Analgesics, Opioid
Anesthetics, Dissociative
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on October 09, 2015